Long-term survival of favorable-risk patients with metastatic renal cell carcinoma treated with second-line axitinib in a multicenter phase II study.

被引：0
|
作者：
Tsimafeyeu, Ilya [1 ]
Borisov, Pavel S. [2 ]
Semenov, Andrey [3 ]
Leonenkov, Roman [4 ]
Novikova, Olga [5 ]
Gamayunov, Sergey [6 ]
Mikhailova, Nadezhda [7 ]
Bondarenko, Anastasia [8 ]
Abdelgafur, Ahmed [6 ]
机构：
[1] Kidney Canc Res Bur, Moscow, Russia
[2] City Clin Oncol Ctr, St Petersburg, Russia
[3] Ivanovo Canc Ctr, Ivanovo, Russia
[4] St Petersburg City Canc Ctr, St Petersburg, Russia
[5] Khabarovsk Reg Canc Ctr, Khabarovsk, Russia
[6] Republican Clin Oncol Ctr, Cheboksary, Russia
[7] Republican Clin Oncol Ctr, Kazan, Russia
[8] IM Sechenov First Moscow State Med Univ, Moscow, Russia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.332
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
332
引用
收藏
页数：2
相关论文
共 50 条
  • [31] RECORD-4: A multicenter, phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Motzer, Robert
    Alyasova, Anna
    Ye, Dingwei
    Karpenko, Andrey
    Li, Hanzhong
    Alekseev, Boris Y.
    Xie, Liping
    Kurteva, Galina Petrova
    Kowalyszyn, Ruben Dario
    Neron, Yeni
    Cosgriff, Thomas
    Collins, LaTonya
    Brechenmacher, Thomas
    Segal, Scott
    Morgan, Liza M.
    Yang, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study
    Qin, Shukui
    Bi, Feng
    Jin, Jie
    Cheng, Ying
    Guo, Jun
    Ren, Xiubao
    Huang, Yiran
    Tarazi, Jamal
    Tang, Jie
    Chen, Connie
    Kim, Sinil
    Ye, Dingwei
    ONCOTARGETS AND THERAPY, 2015, 8 : 1363 - 1373
  • [33] Phase II study of sunitinib as second-line treatment in advanced biliary tract carcinoma: Multicenter, multinational study.
    Yi, J.
    Thongprasert, S.
    Doval, D.
    Lee, J.
    Cho, M. N.
    Park, S. H.
    Park, J. O.
    Park, Y. S.
    Kang, W. K.
    Lim, H. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] A LONG-TERM SURVIVAL IN METASTATIC PAPILLARY RENAL CELL CARCINOMA TREATED WITH TARGETED THERAPIES
    Roberto, Michela
    Bassanelli, Maria
    Giacinti, Silvana
    Poti, Giulia
    Macrini, Serena
    Aschelter, Anna Maria
    Marchetti, Paolo
    ANTICANCER RESEARCH, 2017, 37 (04) : 2087 - 2088
  • [35] Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study
    Pinto, Alvaro
    Reig, Oscar
    Iglesias, Clara
    Gallardo, Enrique
    Garcia-del Muro, Xavier
    Alonso, Teresa
    Anguera, Georgia
    Suarez, Cristina
    Munoz-Langa, Jose
    Villalobos-Leon, Laura
    Rodriguez-Sanchez, Angel
    Lainez, Nuria
    Martinez-Ortega, Esther
    Campayo, Marc
    Velastegui, Alejandro
    Rodriguez-Vida, Alejo
    Villa-Guzman, Jose C.
    Mendez-Vidal, Maria J.
    Rubio, Gustavo
    Garcia, Iciar
    Capdevila, Laia
    Lambea, Julio
    Vazquez, Sergio
    Fernandez, Ovidio
    Hernando-Polo, Susana
    Cerezo, Sara
    Santander, Carmen
    Garcia-Marrero, Rosa
    Zambrana, Francisco
    Gonzalez-del Alba, Aranzazu
    Lazaro-Quintela, Martin
    Castellano, Daniel
    Chirivella, Isabel
    Anido, Urbano
    Viana, Antonio
    Garcia, Arancha
    Sotelo, Miguel
    Garrido Arevalo, Maria
    Garcia-Donas, Jesus
    Hernandez, Carolina
    Victoria Bolos, M.
    Llinares, Julia
    Climent, Miguel A.
    CLINICAL GENITOURINARY CANCER, 2022, 20 (01) : 25 - 34
  • [36] Prognostic factors for metastatic renal cell carcinoma treated with second-line targeted therapies
    Rebibo, J. D.
    Pfister, C.
    Giwerc, A.
    Defortescu, G.
    Gouerant, S.
    Di Fiore, F.
    Nouhaud, F. -X.
    PROGRES EN UROLOGIE, 2016, 26 (01): : 16 - 23
  • [37] Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study
    Oya, Mototsugu
    Tomita, Yoshihiko
    Fukasawa, Satoshi
    Shinohara, Nobuo
    Habuchi, Tomonori
    Rini, Brian I.
    Fujii, Yosuke
    Kamei, Yoichi
    Umeyama, Yoshiko
    Bair, Angel H.
    Uemura, Hirotsugu
    CANCER SCIENCE, 2017, 108 (06): : 1231 - 1239
  • [38] A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma
    Kim, Young Saing
    Lee, Soon Il
    Park, Se Hoon
    Park, Silvia
    Hwang, In Gyu
    Lee, Sang-Cheol
    Sun, Jong-Mu
    Lee, Jeeyun
    Lim, Ho Yeong
    CLINICAL GENITOURINARY CANCER, 2016, 14 (01) : 76 - 81
  • [39] Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population
    Jakobsson, Maria
    Strambi, Angela
    Nilsson, Fredrik
    Arpegard, Johannes
    Dalen, Johan
    FUTURE ONCOLOGY, 2024, 20 (20) : 1385 - 1392
  • [40] Updated results of the phase 3 AXIS trial: Axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC)
    Escudier, B.
    Rini, B., I
    Hutson, T. E.
    Gore, M.
    Oudard, S.
    Tarazi, J.
    Rosbrook, B.
    Williams, J. A.
    Kim, S.
    Motzer, R. J.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E81 - U450
12345